Your browser is no longer supported. Please, upgrade your browser.
Settings
ABBV AbbVie Inc. daily Stock Chart
ABBV [NYSE]
AbbVie Inc.
IndexS&P 500 P/E20.81 EPS (ttm)4.29 Insider Own0.09% Shs Outstand1.51B Perf Week-5.94%
Market Cap135.06B Forward P/E10.03 EPS next Y8.89 Insider Trans-3.10% Shs Float1.51B Perf Month-6.79%
Income6.82B PEG1.35 EPS next Q2.01 Inst Own71.70% Short Float2.05% Perf Quarter-6.53%
Sales30.95B P/S4.36 EPS this Y-2.40% Inst Trans0.01% Short Ratio5.45 Perf Half Y-4.71%
Book/sh-2.15 P/B- EPS next Y12.95% ROA9.50% Target Price109.83 Perf Year-1.64%
Cash/sh2.47 P/C36.08 EPS next 5Y15.37% ROE214.60% 52W Range85.24 - 125.86 Perf YTD-7.79%
Dividend3.84 P/FCF22.14 EPS past 5Y1.20% ROI17.80% 52W High-27.43% Beta1.44
Dividend %4.31% Quick Ratio0.70 Sales past 5Y9.00% Gross Margin75.80% 52W Low7.16% ATR2.03
Employees29000 Current Ratio0.80 Sales Q/Q19.20% Oper. Margin32.80% RSI (14)41.03 Volatility2.48% 2.08%
OptionableYes Debt/Eq- EPS Q/Q5.40% Profit Margin20.70% Rel Volume0.47 Prev Close89.18
ShortableYes LT Debt/Eq- EarningsNov 02 BMO Payout72.90% Avg Volume5.69M Price91.34
Recom2.50 SMA20-2.06% SMA50-3.79% SMA200-8.88% Volume2,254,992 Change2.42%
Oct-04-18Reiterated BofA/Merrill Buy $107 → $106
Jun-01-18Downgrade Piper Jaffray Overweight → Neutral
May-30-18Downgrade Credit Suisse Neutral → Underperform
Jan-30-18Reiterated Morgan Stanley Equal-Weight $99 → $131
Jan-29-18Downgrade Leerink Partners Outperform → Mkt Perform
Oct-30-17Reiterated Leerink Partners Outperform $108 → $107
Oct-02-17Upgrade Leerink Partners Mkt Perform → Outperform
Sep-25-17Downgrade UBS Buy → Neutral $79 → $92
Aug-17-17Initiated Evercore ISI Outperform $95
Jun-22-17Upgrade Societe Generale Hold → Buy
Mar-22-17Upgrade Societe Generale Sell → Hold
Oct-31-16Downgrade Credit Suisse Outperform → Neutral
Oct-18-16Initiated Leerink Partners Mkt Perform $70
Sep-08-16Downgrade JP Morgan Overweight → Neutral
Sep-02-16Initiated Raymond James Outperform $82
Jun-08-16Downgrade Morgan Stanley Overweight → Equal-Weight
Apr-06-16Initiated Societe Generale Sell $47
Mar-15-16Initiated Deutsche Bank Hold $63
Feb-23-16Upgrade Citigroup Neutral → Buy
Dec-01-15Downgrade Barclays Overweight → Equal Weight $73 → $72
Oct-16-18 02:00PM  Drug-Price Transparency Wont End the Patent Games Bloomberg
12:38PM  AbbVie Reinforces Leadership in Gastroenterology with New Data Showcasing Research Advancements Across Robust Portfolio at United European Gastroenterology (UEG) Week 2018 PR Newswire
08:28AM  Amgen, Novartis kick off fight for AbbVie blockbuster drug in EU Reuters
07:00AM  [$$] Biosimilar Humira Goes on Sale in Europe, Widening Gap With U.S. The Wall Street Journal
07:00AM  [$$] The Strategies AbbVie Employed to Protect Humira From Copycats The Wall Street Journal
Oct-15-18 03:50PM  IMPORTANT DEADLINE NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against AbbVie Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE
03:15PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in AbbVie Inc. of Class Action Lawsuit and Upcoming Deadline ABBV ACCESSWIRE
03:00PM  CLASS ACTION UPDATE for COCP, ABBV and ALNY: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
09:48AM  Company News For Oct 15, 2018 Zacks
09:37AM  AbbVie Inc. Investor Alert: Law Offices of Andrew J. Brown Investigates Possible Breaches of Fiduciary Duty by Officers and Directors GlobeNewswire
07:00AM  Health Canada Approves Label Update for AbbVie's HUMIRA® (adalimumab) Supporting Potential For Use During Breastfeeding and Use During Pregnancy if Clearly Needed CNW Group
Oct-14-18 10:05AM  SHAREHOLDER ALERT: QRTEA TRCO PVG USAT COCP TGTX ABBV CPB CHGG ACHC: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines GlobeNewswire
Oct-12-18 08:50PM  IMPORTANT SHAREHOLDER ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against AbbVie Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE
06:50PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in AbbVie Inc. of Class Action Lawsuit and Upcoming Deadline - ABBV ACCESSWIRE
03:29PM  AbbVie Permits US Sale of Sandoz's Humira Biosimilar GuruFocus.com
01:00PM  The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of NVRO, LOGM, USAT, ABBV and ALNY GlobeNewswire
11:40AM  AbbVie Losses Alert: Bernstein Liebhard LLP Reminds Investors of the Important Upcoming Deadline in the Shareholder Class Action Lawsuit Against AbbVie Inc. - ABBV GlobeNewswire
10:25AM  Pharma Stock Roundup: ABBV, NVS' Humira Biosimilar Agreement, BMY's New Cancer Deal Zacks
10:00AM  SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against AbbVie Inc. (ABBV) & Lead Plaintiff Deadline November 20, 2018 GlobeNewswire
09:23AM  AbbVie Settles With Novartis to Delay Humira Biosimilar in US Zacks
08:14AM  Abbvie settles Humira patent disputes with Novartis unit Reuters
07:34AM  The Daily Biotech Pulse: FDA Thumbs Down For Trevena, Corium To Go Private, Immune Design Discontinues Cancer Vaccine Program Benzinga
Oct-11-18 09:30PM  Abbvie settles Humira patent disputes with Novartis unit Reuters
06:04PM  Abbvie settles Humira patent disputes with Novartis unit Reuters
05:48PM  CLASS ACTION UPDATE for ABBV, MGTI and SFIX: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
05:05PM  IMPORTANT SHAREHOLDER NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against AbbVie Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE
04:56PM  AbbVie stock ticks higher as Humira patent dispute with Novartis resolved MarketWatch
04:35PM  Can biotech thrive in a highrise? One developer discovers that it can American City Business Journals
04:32PM  AbbVie Announces Global Resolution of HUMIRA® (adalimumab) Patent Disputes with Sandoz PR Newswire
02:09PM  SHAREHOLDER ALERT: TRCO USAT MCHP COCP ABBV ALNY MGTI CHGG ADNT: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines GlobeNewswire
Oct-10-18 05:45PM  AbbVie (ABBV) Stock Moves -1.54%: What You Should Know Zacks
02:55PM  CLASS ACTION UPDATE for ABBV, ALNY and ADNT: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
01:10PM  IMPORTANT SHAREHOLDER ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against AbbVie Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE
12:59PM  SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In AbbVie Inc. (NYSE: ABBV) To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit GlobeNewswire
10:35AM  J&J's Stelara Succeeds in Phase III Ulcerative Colitis Study Zacks
Oct-09-18 05:12PM  Pomerantz Law Firm Announces the Filing of a Class Action against AbbVie Inc. and Certain Officers ABBV GlobeNewswire
01:33PM  The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of USAT, MCHP, ABBV, ALNY and CPB GlobeNewswire
Oct-08-18 05:14PM  3 Top Biotech Stocks to Buy in October Motley Fool
04:35PM  SHAREHOLDER ALERT: SKX PM USAT MCHP ABBV ALNY MGTI CPB CHGG ADNT: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines GlobeNewswire
11:51AM  AbbVie's Orilissa Gets Canadian Nod to Treat Endometriosis Zacks
08:33AM  AbbVie to Present New Data for Upadacitinib and HUMIRA® (adalimumab) at the 2018 ACR/ARHP Annual Meeting PR Newswire
Oct-07-18 11:17AM  CLASS ACTION UPDATE for COCP, ABBV and ALNY: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
09:00AM  Nobel Prizes Bring Out the Best and Worst in Pharma Bloomberg
Oct-06-18 12:00PM  ABBV LOSS NOTICE: Rosen Law Firm Files First Securities Class Action Lawsuit against Abbvie Inc. ABBV Business Wire
Oct-05-18 05:28PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AbbVie Inc. - ABBV GlobeNewswire
05:13PM  AbbVie Receives Health Canada Approval of ORILISSA (elagolix) for the Treatment of Moderate to Severe Pain Associated with Endometriosis CNW Group
12:46PM  SHAREHOLDER ALERT: PVG OPK USAT TRCO MCHP COCP ABBV: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines GlobeNewswire
12:05PM  AbbVie Inc. Financial Shareholder Alert: Former SEC Attorney Willie Briscoe Investigates Possible Breaches of Fiduciary Duty by Officers and Directors ACCESSWIRE
11:45AM  Pawar Law Group Announces a Securities Class Action Lawsuit Against AbbVie Inc. - ABBV ACCESSWIRE
Oct-04-18 10:30AM  IMPORTANT SHAREHOLDER ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against AbbVie Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE
10:00AM  SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against AbbVie Inc. (ABBV) & Lead Plaintiff Deadline November 20, 2018 GlobeNewswire
03:20AM  Moody's: Biosimilars a growing challenge biotech drugs, with European market developing more quickly than the US Moody's
Oct-03-18 08:30PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AbbVie Inc. - ABBV ACCESSWIRE
07:33PM  Top 5 Biotech Stocks for 2018 Investopedia
06:49PM  Cramer's lightning round: The sweet spot for buying shares of Clorox CNBC
11:14AM  Here's Why J&J (JNJ) is a Good Bet in a Troubled Market Zacks
10:10AM  Why AbbVie (ABBV) is Poised to Beat Earnings Estimates Again Zacks
09:26AM  The hidden dangers of testosterone replacement therapy you should know about CNBC
08:17AM  Nobel Recognizes Science Leading to AbbVie's Top-Selling Drug Bloomberg
Oct-02-18 04:14PM  5 Health Care Stocks Gurus Are Buying GuruFocus.com
12:52PM  Here's Why Antares Pharma Jumped Higher Today Motley Fool
08:41AM  The Zacks Analyst Blog Highlights: ExxonMobil, Disney, AbbVie, Bristol-Myers and United Continental Zacks
Oct-01-18 08:15PM  IMPORTANT DEADLINE REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against AbbVie Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE
04:33PM  ALERT: Pawar Law Group Announces a Securities Class Action Lawsuit Against AbbVie Inc. - ABBV ACCESSWIRE
03:49PM  AbbVie Class Action Lawsuit: Bernstein Liebhard LLP Announces That a Securities Class Action Lawsuit Has Been Filed Against AbbVie Inc. - ABBV GlobeNewswire
11:45AM  5 Reasons to Buy Gilead Stock Today InvestorPlace
10:47AM  Top Analyst Reports for ExxonMobil, Disney & AbbVie Zacks
07:30AM  Research Report Identifies AbbVie, NMI, Dollar Tree, Scotts Miracle-Gro, Halliburton, and Microchip Technology with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Sep-30-18 03:30PM  Here's What Could Cause Neurocrine Biosciences Shares to Skyrocket Motley Fool
08:44AM  Better Buy: AbbVie Inc. vs. Eli Lilly and Company Motley Fool
Sep-28-18 07:15PM  RM LAW Announces Class Action Lawsuit Against AbbVie Inc. PR Newswire
06:06PM  Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of AbbVie Inc. Investors Business Wire
05:45PM  AbbVie (ABBV) Stock Moves 0.47%: What You Should Know Zacks
03:54PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AbbVie Inc. - ABBV GlobeNewswire
03:15PM  SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against AbbVie Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE
03:00PM  CLASS ACTION UPDATE for MCHP, ABBV and ALNY: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
11:33AM  Healthcare: 2 Hot Biotech Stocks on Our Radar Motley Fool
10:23AM  SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against AbbVie Inc. (ABBV) & Lead Plaintiff Deadline - November 20, 2018 ACCESSWIRE
10:10AM  ABBV ALERT: Rosen Law Firm Reminds AbbVie Inc. Investors of Deadline in Class Action Business Wire
Sep-27-18 04:20PM  IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against AbbVie Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE
03:07PM  SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against AbbVie Inc. (ABBV) & Lead Plaintiff Deadline - November 20, 2018 PR Newswire
10:50AM  SHAREHOLDER ALERT: Pawar Law Group Announces a Securities Class Action Lawsuit Against AbbVie Inc. - ABBV ACCESSWIRE
Sep-26-18 08:00PM  Gilead Sciences' Latest Tactic? Go Generic Motley Fool
03:45PM  Gilead Is Undercutting Its Own Drugs: Here's Why Motley Fool
03:31PM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of AbbVie Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of November 20, 2018 ABBV GlobeNewswire
10:18AM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of AbbVie Inc. (ABBV) PR Newswire
Sep-25-18 04:59PM  ABBVIE INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $500,000 Investing In AbbVie Inc. To Contact The Firm Business Wire
Sep-24-18 08:00PM  Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against AbbVie Inc. (ABBV) GlobeNewswire
04:33PM  Hagens Berman Alerts Investors in AbbVie Inc. (NYSE: ABBV) to the November 20, 2018 Securities Class Action Lead Plaintiff Deadline GlobeNewswire
03:58PM  CLASS ACTION ALERT: Brower Piven Notifies Investors of Class Action Lawsuit And Encourages Those Who Have Significant Losses From Investment In AbbVie Inc. (NYSE: ABBV) To Contact Brower Piven Before The Lead Plaintiff Deadline GlobeNewswire
02:58PM  ABBVIE INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $500,000 Investing In AbbVie Inc. To Contact The Firm PR Newswire
11:54AM  IMPORTANT INVESTOR NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against AbbVie Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Business Wire
10:25AM  AbbVie/Roche's Leukemia Drugs Combo Gets CHMP Backing in EU Zacks
07:00AM  AbbVie Class Action: Bernstein Liebhard LLP Announces That a Securities Class Action Lawsuit Has Been Filed Against AbbVie Inc - ABBV GlobeNewswire
Sep-23-18 11:00AM  The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of TRCO, COCP and ABBV GlobeNewswire
10:28AM  AbbVie Class Action: Bernstein Liebhard LLP Announces That A Securities Class Action Lawsuit Has Been Filed Against AbbVie Inc. - ABBV PR Newswire
Sep-22-18 12:35AM  U.S. Probes Drugmakers Over Free Services The Wall Street Journal
Sep-21-18 11:33PM  EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against AbbVie Inc. ABBV Business Wire
05:45PM  AbbVie (ABBV) Dips More Than Broader Markets: What You Should Know Zacks
05:05PM  Hagens Berman Alerts Investors in AbbVie Inc. (ABBV) to the Firm's Investigation of Possible Humira-Related Health Insurance Fraud and Disclosure Violations PR Newswire
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company offers HUMIRA, a biologic therapy administered as a subcutaneous injection for autoimmune diseases; IMBRUVICA, an oral therapy for patients with chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy, with or without ribavirin, to treat adults with genotype 1 chronic hepatitis C. It also provides Kaletra, an anti- human immunodeficiency virus (HIV)-1 medicine used with other anti-HIV-1 medications to maintain viral suppression in HIV-1 patients; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and Synagis to prevent RSV infection at-risk infants. In addition, the company offers AndroGel, a testosterone replacement therapy for males diagnosed with symptomatic low testosterone; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid to treat hypothyroidism; and Lupron, a product for the palliative treatment of prostate cancer, endometriosis, and central precocious puberty, as well as for the treatment of patients with anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Sevoflurane, an anesthesia product for human use; and ZINBRYTA, a subcutaneous treatment for relapsing forms of multiple sclerosis. It serves wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from its distribution centers and public warehouses. AbbVie Inc. has collaboration with Alector, Inc.; C2N Diagnostics; Voyager Therapeutics, Inc.; Janssen Biotech, Inc.; International Myeloma Foundation; Calibr and Scripps Research; The Institute for Research in Immunology and Cancer Commercialization of Research; the Universite de Montreal; Tolero Pharmaceuticals, Inc.; and Bristol-Myers Squibb Company. The company was incorporated in 2012 and is based in North Chicago, Illinois.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SEVERINO MICHAELEVP, R&D and CSOAug 17Sale97.5250,0004,876,06082,281Aug 21 04:58 PM
TILTON GLENN FDirectorJun 27Buy91.905,400496,27439,735Jun 29 02:30 PM
RAPP EDWARD JDirectorJun 20Buy98.631,01399,90920,743Jun 22 05:56 PM
ALBAN CARLOSEVP, Commercial OperationsMar 01Option Exercise29.2348,1001,405,795178,547Mar 02 05:29 PM
CHASE WILLIAM JEVP, Chief Financial OfficerMar 01Option Exercise25.9132,400839,339197,263Mar 02 05:28 PM
Schumacher Laura JExecutive Vice PresidentMar 01Sale117.8525,0002,946,14898,317Mar 02 05:28 PM
CHASE WILLIAM JEVP, Chief Financial OfficerMar 01Sale114.5032,4003,709,687164,863Mar 02 05:28 PM
ALBAN CARLOSEVP, Commercial OperationsMar 01Sale114.3980,9959,264,80897,552Mar 02 05:29 PM
Michael Robert A.VP, ControllerFeb 28Sale119.434,294512,8536,876Mar 02 05:31 PM
SALEKI-GERHARDT AZITASVP, OperationsFeb 28Sale117.771,337157,45893,312Mar 02 05:31 PM
SEVERINO MICHAELEVP, R&D and CSOFeb 28Sale117.932,643311,684132,281Mar 02 05:30 PM
RICHMOND TIMOTHY J.SVP, Human ResourcesFeb 28Sale118.6718,1292,151,45217,588Mar 02 05:30 PM
CHASE WILLIAM JEVP, Chief Financial OfficerFeb 28Sale119.4438,5284,601,954164,863Mar 02 05:28 PM
ALBAN CARLOSEVP, Commercial OperationsFeb 28Sale117.852,579303,928130,447Mar 02 05:29 PM
GONZALEZ RICHARD AChairman of the Board and CEOFeb 28Sale117.888,280976,084313,012Mar 02 05:28 PM
Michael Robert A.VP, ControllerFeb 20Sale120.31992119,35113,557Feb 20 06:08 PM
RICHMOND TIMOTHY J.SVP, Human ResourcesDec 18Option Exercise35.8887,0403,122,995113,118Dec 19 06:09 PM
RICHMOND TIMOTHY J.SVP, Human ResourcesDec 18Sale98.4587,0408,569,05326,078Dec 19 06:09 PM
Schumacher Laura JExecutive Vice PresidentDec 15Option Exercise35.881,14341,011106,875Dec 15 05:13 PM
Schumacher Laura JExecutive Vice PresidentDec 14Option Exercise35.88144,3675,179,888250,099Dec 15 05:13 PM
GONZALEZ RICHARD AChairman of the Board and CEONov 21Option Exercise58.88218,19312,847,204492,030Nov 24 04:55 PM
GONZALEZ RICHARD AChairman of the Board and CEONov 21Sale94.01218,19320,511,800273,837Nov 24 04:55 PM
SEVERINO MICHAELEVP, R&D and CSONov 10Sale94.6925,6332,427,212114,922Nov 13 05:26 PM
Gosebruch Henry OChief Strategy OfficerOct 30Sale90.5518,3001,657,03765,137Oct 31 05:04 PM